AlphAIAlphAI — Financial news for AI agents
Zacks CommentaryOCT 293 min read$STEM

Stem, Inc. (STEM) Reports Q3 Loss, Lags Revenue Estimates

Stem (STEM) delivered earnings and revenue surprises of -53.51% and -6.97%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Original reporting
Zacks Commentary · Zacks Equity Research
Published Oct 29, 2025, 10:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 30, 2025, 12:31 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Stem, Inc. (STEM) Reports Q3 Loss, Lags Revenue Estimates — source image
Source · www.zacks.com
Decision brief

The 30-second read

$STEMNeutralMed
01

Why it matters

The earnings shortfall may lead to a temporary decline in the stock, affecting investor sentiment.

02

Market read

The news has moderate relevance for energy storage investors, with potential short-term trading opportunities.

03

What to watch

Potential upcoming catalysts such as new contracts or technological advancements that could offset recent earnings issues.

Timing: Immediate to short-term (next 1-2 weeks)

Background

Stem Inc. reported Q3 earnings with significant misses, raising concerns about short-term performance.

Company-level read

Ticker impact

$STEMNeutralMedium confidence
Context

Moderate relevance due to recent earnings miss but neutral sentiment.

Expected impact

Potential short-term decline of 5-10%, depending on market reaction.

Evidence & confidence

The earnings miss (-53.51%) and revenue shortfall (-6.97%) suggest bearish sentiment, but neutral overall market sentiment tempers immediate impact.

Market effects

Sector

The earnings miss in the energy storage sector may lead to cautious trading in related stocks.

Regional

Limited regional impact; primarily affects US-based energy storage companies.

Global

Low; the news is company-specific with minimal global market implications.

Counterpoint

What could challenge this read

The earnings miss may be an anomaly; if the company can execute on future projects, the stock could rebound.

Key entities

  • Company
    Stem Inc.

    A provider of energy storage solutions.

Read at source← All news

Related articles

AUG 12
$STEMMed

Stem, Inc.: Stem's PowerTrack EMS Enables Hybridization of Two Operating Utility-Scale Solar Plants in Hungary

Stem, Inc. (NYSE: STEM) said Solarmarkt Group, with EPC partner Pannonwatt, selected Stem’s PowerTrack Energy Management System to hybridize two operating utility-scale solar plants in Hungary. The five-year agreement covers adding 40 MW/80 MWh batteries to each site, targeting commercial operation by Sept 2026 and participation in Hungary’s aFRR market.

finanznachrichten.de3 min
AUG 12
$STEMMed

STEM, INC. (STEM): Completion of Acquisition or Disposition of Assets

STEM, INC. (STEM) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99 Stem Announces Second Quarter 2026 Results Achieved fifth consecutive quarter of positive adjusted EBITDA PowerTrack TM software revenue up 11% YoY PowerTrack TM Energy Management System (EMS) recognized as leading, global innovative solution with The smarter E AWARD w

SEC EDGAR 8-K6 min
JUL 28
$PSKYMed

Why Did PSKY, UBER, STEM Stocks Plummet To 52-Week Lows?

Stocks of Paramount Skydance (PSKY), Uber (UBER) and Stem (STEM) hit 52-week lows. PSKY fell after delaying its Warner Bros. Discovery merger to June 1, 2027 amid a multistate antitrust suit. UBER dropped on slower growth and Waymo partnership concerns. STEM slid on EV charging weakness and Barclays cut its price target to $8; revenue fell 11% to $29M.

stocktwits.com4 min
SEP 25
$NKTRMed

Nektar Therapeutics Wins $90M Lilly Verdict

A jury awarded Nektar Therapeutics $90M in damages after finding Eli Lilly breached a license agreement. Nektar said the verdict is subject to post-trial proceedings and appeals. The dispute involves a collaboration for developing rezpegaldesleukin. Nektar Therapeutics (NASDAQ:NKTR) and Eli Lilly (NYSE:LLY) are involved.

grafa.com2 min